Reproductive Health
Non-Invasive Prenatal Testing (NIPT)
NIPT is a screening test that can screen for partial duplications and deletions and aneuploidy status for all autosomes, sex chromosome abnormalities, and common chromosomal conditions including trisomy 21, trisomy 18, and trisomy 13.
he NIPT workflow consists of several steps. The complexity of these steps varies widely between tests and the technical approach used. The workflow starts with isolating plasma from the blood draw. Cell-free DNA (cfDNA) is extracted from plasma and prepared for analysis.
Illumina NIPT uses whole-genome next-generation sequencing (NGS) technology. The test analyzes cfDNA fragments across the whole genome, which has advantages over other NIPT methodologies, including targeted sequencing and array-based tests.
When evaluating NIPT technologies, consider data generation and analysis, lab workflow, and resulting clinical implications.
ACOG and SMFM guidelines recommend noninvasive prenatal testing for all
ACOG and SMFM guidelines endorse NIPT for all pregnant patients regardless of age or baseline risk. ACOG’s recommendations positively impact the quality of care for expectant mothers in more ways than one. This kind of unprecedented access will empower more parents to prepare and make informed pregnancy decisions.
he NIPT workflow consists of several steps. The complexity of these steps varies widely between tests and the technical approach used. The workflow starts with isolating plasma from the blood draw. Cell-free DNA (cfDNA) is extracted from plasma and prepared for analysis.
Illumina NIPT uses whole-genome next-generation sequencing (NGS) technology. The test analyzes cfDNA fragments across the whole genome, which has advantages over other NIPT methodologies, including targeted sequencing and array-based tests.
When evaluating NIPT technologies, consider data generation and analysis, lab workflow, and resulting clinical implications.
Broad test menu expands prenatal screening beyond aneuploidies 21, 18, and 13 to all rare autosomal aneuploidies (RAAs), sex chromosome aneuploidies (SCAs) and partial duplications and deletions ≥ 7 Mb for all autosomes. As a result, VeriSeq NIPT v2 detects anomalies that targeted assays miss to deliver more insights into the health of a pregnancy.
Comprehensive in-lab NIPT IVD solution including reagents, instruments, and software for accurate aneuploidy screening results in 26 hours.
- A simple, easy-to-use, automated IVD prenatal screening solution that easily integrates into your lab’s current workflow and flexes with your lab’s growing needs
- ≥ 99.9% sensitivity and specificity for trisomy 21, 18, and 131
- Fast workflow with minimal hands-on time, enabling sample to report in ~26 hours
Broad test menu expands prenatal screening beyond aneuploidies 21, 18, and 13 to all rare autosomal aneuploidies (RAAs), sex chromosome aneuploidies (SCAs) and partial duplications and deletions ≥ 7 Mb for all autosomes. As a result, VeriSeq NIPT v2 detects anomalies that targeted assays miss to deliver more insights into the health of a pregnancy.
